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Post-traumatic stress disorder (PTSD) has been associated with an inflammatory state. 
However, few studies have addressed the mechanisms underlying this immune imbal-
ance that favors inflammation or how this imbalance contributes to PTSD. Whether the 
immune imbalance influences responsiveness or unresponsiveness of patients to PTSD 
treatments is currently not known. This review brings forward an immune emphasis to a 
mental health disorder that is unprecedented in its prevalence among combat Veterans 
of the ongoing conflicts in Iraq and Afghanistan and which also afflicts civilians who 
have undergone extreme traumatic experiences, such as following natural disasters, 
serious accidents, or assaults. Included is an overview of the correlative associations 
in human subjects between PTSD and inflammation and studies in animal models of 
PTSD, demonstrating causal contributions of inflammation and immune dysregulation to 
PTSD-like behavior following stress exposure.
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inTRODUCTiOn
Over 2.5 million U.S. service members have been deployed at Operation Enduring Freedom/Operation 
Iraqi Freedom (OEF/OIF) arenas since 2001, with an unprecedented proportion (15.7%) of them 
developing post-traumatic stress disorder (PTSD) following combat exposure (1, 2). The disorder is 
not limited to combat but is also seen in civilians following natural disasters, sexual trauma, or loss of 
family members (3, 4). PTSD is a debilitating disorder that develops after exposure to traumatic events. 
It is characterized by clusters of symptoms including re-experiencing the traumatic event, avoidance 
of trauma-related stimuli, general changes in mood and cognition, and hyperarousal symptoms. 
PTSD has a social and an economic impact on the afflicted individual and the community at large, 
and these affects can be long term. For example, 23 years after an earthquake experience, survivors 
exhibited PTSD anxiety symptoms and reduced quality of life (5). PTSD and depression were shown 
to worsen over time (1 year) following a major hurricane, with a doubling of the proportion of affected 
individuals with suicidal thoughts (6). The most comprehensive analysis of the impact of PTSD has 
been conducted with Veterans, but it has been suggested that the financial impact also applies to the 
civilian population with PTSD (7). Veterans with conflict-related PTSD and non-Veterans with PTSD 
have increased rates of substance use, other comorbidities, suicide, homelessness, unemployment, 
and reduced quality of life (2, 7, 8). A cost analysis showed that, of the high-cost patients to the VA 
health-care system, 17% were due to PTSD, and their high cost was attributed to increase number of 
inpatient stays, increased length of stay, and increased outpatient visits (9).
In the past two decades, psychological and pharmacological treatments have been developed for 
PTSD, but many patients do not respond to these treatments, placing them at risk for developing 
a chronic illness with poor long-term outcomes (10). Pharmacological treatment of Veterans with 
TABLe 1 | Overview of studies with human subjects with PTSD.
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⍰ Reduced anti-
inflammatory cytokines IL-4 
and TGF-β
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pro-inflammatory  
Th1 and Th17
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Effect of treatment on 
immune imbalance
⍰ Reduced IL-1 and 
TNF-α
⍰ Restoration of Treg levels
□✓ Strong experimental support; ⍰ some support, but more studies are needed.
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PTSD is limited by there being only two FDA-approved drugs for 
PTSD: sertraline and paroxetine. Both sertraline and paroxetine 
are in the class of selective serotonin reuptake inhibitors (SSRIs). 
Unfortunately, responsiveness to these first-line pharmacothera-
pies is suboptimal at 50–60% (11–14). Unknown is why combat 
Veterans appear to be more resistant to treatment with SSRIs than 
civilians (15). Also unclear is why some individuals respond to 
SSRIs and others do not. While only approximately half of the 
Veterans with PTSD respond to these first-line SSRIs, full remis-
sion is only 20–30% (11–14). Since there are no biomarkers to 
predict responsiveness to SSRI treatment, this leaves many PTSD 
subjects with the financial and emotional cost of ineffective 
treatments.
In the past decade, there has been an effort to identify the 
biological causes of PTSD. This effort has suggested that the 
biological dysfunction can result from immune alterations asso-
ciated with PTSD (16), but relatively few studies have investigated 
immune functions in PTSD patients, and the results have been 
both unclear and contradictory. However, a compilation of the 
results indicates the presence of an excessive inflammatory state 
in subjects with PTSD (17–25), although the precise mechanisms 
of pathogenesis of PTSD remain unclear.
CORReLATiOnS BeTween 
inFLAMMATiOn AnD PTSD
Studies involving human subjects with PTSD have indicated a 
linkage between immune alterations and PTSD following trauma 
exposure, though it is unlikely that the primary cause of PTSD is 
immune-mediated. Measurement of the various immune media-
tors including pro-inflammatory cytokines in PTSD subjects has 
been somewhat haphazard, but collectively, the results of these 
studies have suggested immune alterations toward increased 
levels of inflammatory cytokines (4, 18, 19, 24, 26). An overview 
of these studies is in Table 1. These analyses have shown skewing 
toward increases in levels of pro-inflammatory cytokines, such 
as IL-1, IL-6, and TNF-α (4, 18, 19, 22, 24, 26). While levels of 
anti-inflammatory cytokines have been less frequently measured 
in subjects with PTSD, there have been some studies indicating 
reduced levels of these anti-inflammatory mediators, including 
IL-4 and TGF-β (19, 26). However, in a separate study, both 
inflammatory and anti-inflammatory cytokines were shown to 
be elevated in PTSD subjects, leading to a conclusion of a general-
ized immune activated state in PTSD (27).
The imbalances in cytokines in subjects with PTSD are reflected 
not only by increased plasma levels of inflammatory cytokines but 
also by imbalances in immune cell compositions. This is seen by 
increases in peripheral blood levels of pro-inflammatory Th1 and 
Th17 cells and reduced numbers of anti-inflammatory cells, such 
as Treg (18, 22). Levels of the negative regulator PD-L1 on CD4+ 
cells from PTSD patients are also reduced, further illustrating the 
immune skewing toward a dysregulated state (28).
Consistent with the pro-inflammatory skewing seen in 
subjects with PTSD is an increased incidence of allergies in this 
population. For example, the incidence of adult-onset asthma 
was shown to be increased subsequent to PTSD-associated 
trauma (29). A comparison between study participants with or 
without chronic idiopathic urticaria (CIU) showed the severity 
of PTSD to be greater in those with CIU, although the sequence 
of the appearance of the comorbidities was not determined (30). 
A retrospective study of Iraq and Afghanistan Veterans who were 
enrolled in the VA health-care system showed that those with 
PTSD had an increase in incidence of subsequently developing 
autoimmune diseases, such as thyroiditis, inflammatory bowel 
disease, multiple sclerosis, rheumatoid arthritis, and systemic 
lupus erythematosus (31). Interestingly, the reverse was not 
seen. Those with preexisting autoimmune disorders did not have 
an increased incidence of PTSD, indicating the severity of the 
immune imbalance following the traumatic episode.
Because of the direct association between skewed immune 
reactivity toward increased levels of inflammatory cytokines and 
disease severity in combat-exposed Veterans with PTSD, it has 
been suggested that immune activation is a contributor to their 
clinical status (20). A prospective study of deployed Marines 
showed that pre-deployment levels of C-reactive protein, an 
indicator of inflammation, predicted post-deployment PTSD 
and suggested inflammation to be a contributor to PTSD (32). 
A study of hospitalized patients with traumatic orthopedic inju-
ries showed that those who subsequently developed PTSD had 
increased blood levels of inflammatory mediators and reduced 
anti-inflammatory mediators and suggested that this could be 
used as a biomarker for PTSD (19). However, at present, these 
suggestions may be premature as biomarkers for PTSD have yet 
to be clearly defined.
Assessments of inflammatory cytokine levels in the cerebral 
spinal fluid of subjects with and without PTSD have not been 
extensively measured. However, the results of such studies are 
conflicting, with demonstrations of both increases and no dif-
ference in levels of IL-6 among subjects with and without PTSD 
(33, 34). In contrast, studies have also shown increased levels 
of inflammatory mediators in saliva following stress exposure, 
although such studies of salivary cytokine levels are very few 
(3, 35). In one of these few studies, levels of the inflammatory 
mediator monocyte chemotactic protein (MCP-1) in the saliva of 
hurricane survivors with PTSD correlated with PTSD severity (3). 
It has previously been suggested that levels of immune mediators 
in the saliva can be influenced by sympathetic nervous system 
innervation, rather than being secondary to blood levels of the 
TABLe 2 | Overview of studies with animal models of PTSD that provide a 
causal immune–PTSD association.
Trigger immune response Causality
Severe stressor Increased brain IL-1 Blocking IL-1 prevents 
fear response
Induction of peripheral 
inflammation
Increased brain levels of 
inflammatory cytokines 
IL-1, IL-6, and TNF-α
Block NF-κB reduces 
IL-1 and anxiety
Social defeat stress Monocyte trafficking from 
spleen to brain
Splenectomy prevents 
monocyte trafficking and 
anxiety
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mediators (35, 36). This suggestion comes from demonstrations 
of earlier appearance of inflammatory cytokines in saliva follow-
ing an acute stress than the increases that were seen systemically. 
Thus, salivary cytokine levels may be more reflective of mental 
health status than would plasma cytokine levels, but there has 
as yet not been sufficient studies to make definitive conclusions.
The plasticity of immune cells is driven by the cytokine milieu 
and raises the question of whether the inflammation-skewed 
immune reactivity of PTSD patients can undergo rebalancing. 
While studies have shown an imbalance toward inflammatory 
immune reactivity in PTSD patients, less clear is whether recov-
ery from PTSD restores the immune balance. In fact, there are 
surprisingly few studies examining if clinical improvements of 
PTSD are accompanied by immune normalization. In one such 
study, women with PTSD had elevated levels of inflammatory 
cytokines, but those who recovered from PTSD had reduced 
levels of inflammatory cytokines that were similar to levels in 
healthy women who had not experienced trauma (37). Also 
suggesting immune rebalancing is demonstration of a shift from 
reduced levels of anti-inflammatory Treg cells in PTSD patients 
toward increased Treg levels upon narrative exposure therapy 
(17). Levels of the inflammatory cytokines IL-1 and TNF-α were 
reduced, and mental parameters improved following treatment 
of Veterans with a fermented soy product to normalize the blood 
steroidal hormone cascade (38).
Modulation of serotonin can directly impact immune activity 
(39–42), and thus, it is not unexpected that the SSRIs approved 
by the FDA for PTSD would have an impact on immune func-
tion. For example, blood levels of the inflammatory mediator 
IL-1 declined from an increased level in individuals with PTSD 
to levels comparable to those of controls following treatment 
with sertraline (43). Studies in which parameters of inflamma-
tion were measured prior to or after SSRI treatment for PTSD 
are relatively rare, but such studies have been conducted with 
SSRI treatment for other conditions. For example, children and 
adolescents who were treated with the SSRI, fluoxetine, for major 
depressive disorder or anxiety disorders had a decline in TNF-α 
levels, although not in levels of IL-6 or IL-1 (44). However, all 
three of these inflammatory cytokines were higher in subjects 
who were clinically resistant to SSRI treatment compared to those 
who responded to SSRI treatment. While the mechanisms for the 
immune quenching have not been fully defined, peripheral blood 
components, such as lymphocytes, monocytes, and platelets, 
contain serotonin. Inhibition of serotonin transporter by SSRIs 
may allow increased uptake through serotonin receptors, thereby 
decreasing immune function (41, 45, 46). Alternatively, studies 
have suggested that SSRIs mediate the immune inhibitory effects 
independently of serotonin transport by depletion of calcium 
stores of T-cells (47). Regardless of the mechanisms by which 
SSRIs mediate immune tempering, treatment of individuals 
having PTSD could impact not only clinical mental status but 
also immune balances. However, this needs to be validated with 
clinical intervention studies monitoring both clinical status and, 
concurrently, immune status. Also needed is analysis of immune 
status in PTSD subjects who are responsive to either psycho-
therapy or pharmacotherapy for PTSD versus those who resist 
treatment responses.
AniMAL MODeLS OF PTSD SUPPORT  
A CAUSAL iMMUne ROLe in PTSD
Studies with animal models have clearly established that the 
immune–brain communications are intimately intertwined. For 
example, immune mediators, such as IL-1, IL-6, and TNF-α, 
are able to cross the blood–brain barrier, and this is one way in 
which peripheral immune reactivity can have CNS impacts (48). 
Induction of peripheral inflammation by intraperitoneal injection 
of mice with endotoxin has been shown to trigger neuroinflam-
mation in the CNS (49–51). This peripheral inflammation results 
in a concomitant increase in the number of activated microglia 
and in levels of inflammatory mediators IL-1, IL-6, and TNF-α in 
the hippocampus and in anxiety-like behaviors.
While animal models for PTSD are imperfect and unable to 
fully mimic PTSD in human subjects, studies using such animal 
models have been more comprehensive and definitive than stud-
ies of PTSD in human subjects. Several animal models for PTSD 
have been established and well characterized (52). An overview of 
the results of studies with animal models for PTSD is in Table 2. 
A commonly used model involves repeated exposure to either the 
rodent’s natural predator (typically cat) or urine of the predator. 
Also used are social stressors such as social housing instability 
induced by daily changes in cage cohorts or social defeat such as 
that induced by repeatedly exposing male mouse cohorts to an 
aggressive intruder mouse. Some studies have used combinations 
of predator exposure with social stressors. A stress-enhanced fear 
learning model involves unpredictable repeated shocks in one 
environment followed by a single shock in a second environment.
Using predator exposure together with social stress of daily 
cage cohort change as a rat PTSD model, it has been shown 
that the dysregulation of cytokines that is seen peripherally in 
human subjects with PTSD is also seen in select brain regions 
where levels of the inflammatory cytokines are increased, while 
levels of the anti-inflammatory cytokines are reduced (19, 26, 53). 
Using a stress-enhanced fear learning model, hippocampal IL-1 
levels were shown to become increased as a result of the severe 
stressor (54). This study further showed that blocking the IL-1 
signaling pathway after the stress exposure prevented the fear 
learning response, suggesting that IL-1 could have a causal role 
in PTSD following trauma exposure. Also supporting immune 
contribution to PTSD-like anxiety is demonstration that anxiety 
in predator scent-stressed mice could be induced by activation of 
the pro-inflammatory NF-κB pathway, which is also increased in 
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activity in human subjects with PTSD (55, 56). Interruption of 
this stress-provoked pro-inflammatory NF-κB pathway by toll-
like receptor 9 (TLR9) activation reduced the elevated IL-1 levels 
and tempered the anxiety levels in the predator-stressed mice 
(55). What appears to be emerging is a critical involvement of the 
NF-κB inflammatory pathway in the anxiety of stress-conditioned 
animals. In fact, treatment of predator scent-stressed rats with 
either corticosterone or a selective NF-κB inhibitor mitigated 
stress behavior (57). This peripheral-CNS exchange is not limited 
to communication via soluble inflammatory mediators. In mice 
that were exposed to repeated social defeat, subthreshold stress 
resulted in trafficking of primed monocytes from the spleen to the 
brain and re-establishment of anxiety behavior (58, 59). However, 
if mice were splenectomized prior to the repeated social defeat, 
the monocyte trafficking and anxiety behavior, that otherwise 
occur following subthreshold stress, were prevented.
Similar to the results of the few studies that have been con-
ducted to assess the impact of SSRIs on inflammatory mediators 
in human subjects (43, 44), studies with a predator-exposure 
animal model for PTSD showed that pharmacotherapy with 
the SSRI, sertraline, lessened the levels of the pro-inflammatory 
mediator IL-1 and signaling through the pro-inflammatory 
receptor TLR4 in the CNS, while increasing the CNS levels of 
anti-inflammatory cytokines IL-4 and IL-10 (53). The anxiety 
behavior and inflammation in the peripheral blood and CNS that 
is induced by treatment of rats with IFN-α could be blocked by 
treatment with the SSRI, paroxetine (60). However, as indicated 
above, serotonin can have direct immune modulating effects (41, 
45, 46), raising the question of whether or not the alleviation of 
anxiety behavior in SSRI-treated animals could be secondary to 
the immunological effects of SSRIs.
CHALLenGeS AnD UnKnOwnS
A significant challenge to studying the immune association with 
PTSD is the variability in the type and severity of trauma expo-
sure that led to PTSD. More conclusive results could be attained 
with a tightly controlled and relatively homogeneous population 
of subjects, with some having PTSD and others not. One such 
population could be Veterans of the currently ongoing conflicts 
in Iraq and Afghanistan, who are likely to be otherwise relatively 
healthy. However, such highly focused and tightly controlled 
studies would have to lead to studies that would be applicable to 
a broader population with PTSD. In studies with either a tightly 
controlled homogeneous population or a broader population with 
PTSD, it would be critical to measure both pro-inflammatory and 
anti-inflammatory cytokines and immune inflammatory and anti-
inflammatory cells since immune reactivity consists of a balance 
between pro-inflammatory and anti-inflammatory forces. While 
studies have measured select pro-inflammatory cytokines, very 
few have also examined the balance between pro-inflammatory 
and anti-inflammatory mediators in subjects with PTSD.
Previously conducted studies that have suggested PTSD to 
be associated with an inflammatory state have traditionally 
measured levels of inflammatory cytokines in the blood plasma. 
However, analyses of cytokines in subjects undergoing other 
forms of stress exposure have shown more prominent immune 
alterations in saliva as opposed to plasma (35, 36). Collection 
of salivary samples for cytokine analysis is less invasive than 
collection of blood, and saliva can be collected more frequently, 
such as before, during, and after therapy sessions (3, 4, 61). In future 
studies, analysis of pro-inflammatory and anti-inflammatory 
cytokines in saliva of PTSD subjects will also need to be analyzed 
in the context of the subjects’ clinical status so as to further deter-
mine if the immune imbalances are more pronounced in subjects 
with more severe PTSD and whether the immune balances are 
restored upon response to therapy for PTSD.
More recent approaches to studying PTSD in humans have 
included advanced neuroimaging approaches and genetic 
approaches. For example, magnetic resonance images showed 
brain structural differences between subjects with and without 
PTSD, including differences in cortical thickness, volumes of 
caudate and right hippocampus, and total cerebral volume (62). 
Diffusion tensor imaging showed differences in measures of brain 
connectivity between subjects with and without PTSD (63). These 
studies have not, as of yet, incorporated the immune status of the 
subject with PTSD. In contrast, genetic analyses for predictors 
of PTSD risk have implicated immune genes as biomarkers. A 
study of pre-deployment military showed that service members 
who eventually developed PTSD had dysregulated expression 
of immune-associated genes, which could be used to predict 
who subsequently develops PTSD (64). However, such results 
should not come as a surprise as they reflect at the genetic level 
the immune dysregulation that has been shown at the protein 
level. However, such studies are starting to address the molecular 
mechanisms that could be underlying the immune skewing 
toward a dysregulated inflammatory state in PTSD (65).
The underwhelming level of responsiveness to treatments for 
PTSD urges the exploration of alternate treatment. If immune–
brain communications are contributors to PTSD following the 
initial trauma, then this opens the possibility of immune inter-
vention. However, immune modulatory treatment approaches 
need to be accompanied by mechanistic studies to define the 
relationships in PTSD between behavior and peripheral and CNS 
immune reactivities. A key question is whether treatment effec-
tiveness with SSRIs is a consequence of immune modulation and 
whether immunological mechanisms bear responsibility when 
SSRI treatment is ineffective. Alternate treatments being tested 
include magnetic brain stimulation (66), but the immunological 
impacts have not been determined. Despite these unanswered 
questions, the culmination of studies from subjects with PTSD 
and from animal models shows that PTSD is not only a behavioral 
disorder but is also an immunological disorder with immune 
imbalances toward an increased pro-inflammatory state and 
diminished anti-inflammatory controls.
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